The present invention relates to an injectable homogeneous aqueous solution of chitosan containing, in a physiologically acceptable medium, between 0.1 and 4.5% by weight of a chitosan having a degree of acetylation less than 20% and a weight average molecular mass of between 100,000 and 1,500,000 g/mol, said solution having a pH greater than or equal to 6.2, and advantageously between 6.2 and 7.2, said solution not containing any chitosan having a degree of acetylation greater than 20%, said solution being liquid and homogeneous at ambient temperature. The invention also relates to an aqueous solution such as previously described, characterised in that it can be prepared by a method comprising at least the following steps: dissolving the chitosan in water by adding acid, such as a weak acid, said weak acid being advantageously chosen from the group consisting of acetic acid, glycolic acid, lactic acid, glutamic acid, and the mixtures of same, and readjusting the pH by dialysis, preferably at ambient temperature, in order to obtain an aqueous solution having a pH greater than or equal to 6.2, advantageously between 6.2 and 7.2, and preferably between 6.25 and 7.1.

The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Polymeric superporous hydrogels, methods for making the same, and wound dressings incorporating the same are disclosed herein. The polymeric superporous hydrogels may be PVA-based hydrogel foams. The polymeric superporous hydrogels may exhibit intrinsic antimicrobial activity against Gram-positive bacteria. The polymeric superporous hydrogels may be well suited for incorporation into wound dressings or the like.

Methods for manufacturing drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate may include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. The methods may include disposing a solution including a monomer and an active compound on the substrate. The methods may also include exposing the solution and the substrate to UV light to initiate polymerization of the solution.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

The present invention relates to a sterile gel formulation suitable for use in filling a wound cavity and delivering an active ingredient thereto, the gel further having a pH range of 4.5 to 8.5, low bioadhesive strength and cohesive integrity and being formed from a polymer selected from among the group consisting of poly(vinyl) alcohol (PVA) polymer and a PVA-polyvinyl acetate copolymer, a cross-linker being a salt form of boron that produces borate ions in aqueous solution, at least one compound which has a beneficial effect as an active ingredient in the wound and at least one modulator, the modulator being a low molecular weight species that is capable of binding borate or PVA in aqueous solution through a mono-diol or di-diol formation and reduces the pH of PVA-borate hydrogels; wherein the gel is heat and/or gamma sterilised and contains less than 5% acetic acid and the polymer has a degree of hydrolysis of between 98% and 100% and a molecular weight of from 100,000 to 300,000 Daltons.

A prosthetic repair system includes a prosthesis for repairing a defect in a tissue or muscle wall. A material delivery device is provided for delivering a material, such as an adhesive material, to a surface of the prosthesis and/or to particular locations between the prosthesis and the tissue or muscle wall to attach the prosthesis to the wall. The delivery device may be coupled to the prosthesis and configured to distribute the material from one side of the prosthesis to an opposite side that is to face the defect. The delivery device may include a manifold and conduits for delivering the material from the manifold to one or more desired locations. The conduits may penetrate into and/or through the thickness of the prosthesis. After delivery and distribution of the material, the delivery device may be removed from the prosthesis and withdrawn from) a patient.

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.